Principal investigators and laboratory managers seeking a reliable PT-141 buy option require verified chemical purity, strict endotoxin controls, and complete lot traceability. PT-141 (Bremelanotide) is a synthetic cyclic peptide melanocortin receptor agonist engineered exclusively for in vitro assaying and preclinical research into central neurosignaling pathways.
Principal investigators and laboratory managers seeking a reliable PT-141 buy option require verified chemical purity, strict endotoxin controls, and complete lot traceability. PT-141 (Bremelanotide) is a synthetic cyclic peptide melanocortin receptor agonist engineered exclusively for in vitro assaying and preclinical research into central neurosignaling pathways.
When evaluating options for a PT-141 buy order, research institutions must prioritize verified chemical identity and quantitative purity over unvalidated commercial claims. PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH). In preclinical models, it functions as a potent agonist across central melanocortin receptors, serving as an important tool for investigating central nervous system control over physiological and behavioral responses.
To ensure reproducible assay results, academic and private laboratories require synthetic peptides that are free from residual counter-ions, truncated sequence fragments, and bacterial endotoxins. Sourcing PT-141 from PX1 Research guarantees lot-specific documentation, including high-performance liquid chromatography (HPLC) chromatograms and mass spectrometry (MS) spectra, supporting rigorous scientific inquiry without confounding variables.
PT-141 is a cyclic heptapeptide derivative of Melanotan II, characterized by the chemical sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Its molecular structure includes a lactam bridge formed between the side chains of the aspartic acid and lysine residues. This structural cyclization confers enhanced conformational stability and enzymatic resistance against degradation by peripheral peptidases compared to linear endogenous peptide signals.
With a molecular weight of approximately 1025.2 g/mol, Bremelanotide possesses a targeted binding profile that allows researchers to explore distinct receptor subtype affinities. The inclusion of D-phenylalanine within the pharmacophore core is critical for its receptor interaction kinetics. Researchers interested in broader receptor cross-talk pathways can reference our comprehensive guide on melanocortin receptor agonists to compare structural modifications across this peptide family.
Preclinical binding assays demonstrate that PT-141 acts as a non-selective agonist at central melanocortin receptors, exhibiting high affinity for the melanocortin-4 receptor (MC4R) and melanocortin-3 receptor (MC3R), alongside measurable activity at MC1R and MC5R. Unlike classical vascular or nitric-oxide-dependent compounds, PT-141 exerts its primary biological influence via central neural circuitry located within the hypothalamus.
Upon agonist binding to MC4R in the paraventricular nucleus (PVN) and medial preoptic area (mPOA) of the brain, downstream intracellular signaling cascades are triggered. In vitro experiments confirm that receptor activation leads to G-protein coupling (Gαs), stimulating adenylate cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP) accumulation. Research models utilize this central activation mechanism to study neurochemical signaling independent of direct peripheral vascular tone.
In animal models, PT-141 has been extensively studied for its role in modulating central melanocortin signaling pathways linked to sexual health pathways and neuroendocrine responses. Rodent investigations demonstrate that central administration of Bremelanotide induces specific appetitive and proceptive behavioral displays, facilitating mapping of the neural circuits governing motivation and autonomic motor output.
Non-human primate studies further elucidate that PT-141 acts downstream of cortical processing center inputs, engaging hypothalamic subnuclei without triggering peripheral adrenergic stimulation. Because it bypassed primary vascular pathways, researchers frequently utilize PT-141 as a selective control compound when differentiating central neurogenic driving forces from peripheral hemodynamic responses in laboratory models.
Understanding the comparative selectivity of central signaling agents is essential when designing experimental assays. While PT-141 was specifically developed to reduce systemic side effects associated with cutaneous MC1R activation, related peptides offer contrasting binding profiles. For instance, Melanotan II exhibits significantly higher potency at the MC1R subtype, making it less specific for isolated central neurological modeling.
In contrast, research protocols targeting upstream neuroendocrine regulatory networks often utilize complementary peptides like Kisspeptin-10 to investigate the gonadotropin-releasing hormone (GnRH) axis, or Oxytocin to examine peripheral bonding and smooth-muscle tone signaling pathways. Evaluating these distinct compounds side-by-side allows laboratory researchers to delineate central melanocortinergic action from alternative neuropeptidergic pathways.
Acquiring research-grade compounds requires stringent vendor verification. A valid PT-141 buy for laboratory use must be accompanied by comprehensive analytical verification from an independent ISO 17025 accredited laboratory. High-Performance Liquid Chromatography (HPLC) analysis must confirm a chemical purity of at least 99.0%, ensuring that synthesis side-products or unreacted sequence precursors are eliminated.
Electrospray Ionization Mass Spectrometry (ESI-MS) is simultaneously utilized to verify the exact molecular mass and sequence integrity of the cyclic structure. Furthermore, because central nervous system tissue models and cellular assays are sensitive to bacterial contamination, PX1 Research evaluates every lot via Limulus Amebocyte Lysate (LAL) testing to confirm that endotoxin content remains strictly below 0.01 EU/mg, protecting cell culture viability.
Proper handling and reconstitution protocols are vital to maintaining peptide integrity prior to laboratory assaying. PT-141 is supplied as a lyophilized, sterile-filtered powder. Reconstitution should be conducted within a laminar flow hood using sterile laboratory diluents, such as sterile bacteriostatic water or phosphate-buffered saline (PBS, pH 7.4), depending on the requirements of the planned assay system.
To reconstitute, introduce the diluent gently down the inner glass wall of the vial rather than spraying directly onto the lyophilized cake. Allow the cake to dissolve completely via gentle swirling without mechanical agitation or vortexing, which can introduce shear stress and lead to peptide denaturation or aggregation. Once reconstituted, stock solutions should be quantified using UV spectrophotometry or micro-BCA assays before dilution into working culture media.
Lyophilized PT-141 exhibits robust long-term stability when stored under controlled atmospheric conditions. Unopened vials should be maintained at -20°C for routine short-term storage or -80°C for extended institutional archiving, protected from light exposure and ambient moisture in a desiccated environment.
Following reconstitution, liquid aliquots are significantly more susceptible to hydrolytic degradation and temperature fluctuations. Reconstituted stock solutions stored at 4°C should be utilized within 14 to 21 days. For long-term project planning, researchers should aliquot the stock into single-use microcentrifuge tubes and store them at -80°C to avoid repetitive freeze-thaw cycles, which compromise structural cyclic integrity.
In vitro models employ PT-141 to map GPCR signaling networks and study receptor desensitization kinetics. Researchers routinely utilize recombinant human MC4R cell lines (such as HEK293 expressing MC4R) to measure competitive binding displacement against radiolabeled ligands like [125I]-NDP-α-MSH. These assays help establish binding affinity constants (Ki) and receptor activation profiles.
Furthermore, intracellular signaling studies utilize fluorescence-based FLIPR or Homogeneous Time-Resolved Fluorescence (HTRF) cAMP assays to evaluate agonist efficacy. By profiling how PT-141 recruits beta-arrestin signaling pathways relative to canonical cAMP pathways, investigators can study biased agonism at melanocortin receptors, publishing foundational data in our open-access research library hub.
PX1 Research serves as a trusted domestic partner for university institutions, contract research organizations (CROs), and private biotechnology facilities requiring uncompromised research compounds. All peptides, including PT-141, are synthesized in US-based, GMP-compliant facilities and undergo thorough analytical testing prior to inventory release.
Orders ship directly from our climate-controlled distribution centers in California and Arizona, guaranteeing rapid, domestic transit times and same-day dispatch for orders placed before standard cutoff times. Principal investigators seeking volume scaling or streamlined supply chains for multi-phase projects can establish direct facility accounts through our dedicated wholesale platform.
What is the purity standard for PX1 Research PT-141?
PX1 Research provides PT-141 with a minimum verified chemical purity of 99.0% as determined by Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC). Electrospray Ionization Mass Spectrometry (ESI-MS) is included with every Certificate of Analysis to confirm exact molecular weight.
What receptor subtypes does PT-141 target in preclinical research?
PT-141 acts primarily as an agonist at the melanocortin-4 receptor (MC4R) and melanocortin-3 receptor (MC3R), with lower affinity activation observed at MC1R and MC5R in competitive binding assays.
How is PT-141 shipped to maintain chemical stability?
PT-141 is shipped in a lyophilized (freeze-dried) state, which exhibits high thermal stability at room temperature during domestic transit. Upon arrival at your laboratory facility, vials should be stored at -20°C or -80°C for long-term preservation.
What solvent is recommended for reconstituting PT-141 in vitro?
For routine laboratory assay preparation, sterile bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4) is recommended. The choice of solvent depends on the specific requirements of the cell culture or cell-free assay system.
What are the endotoxin limits for PX1 Research peptides?
Every lot of PT-141 undergoes Limulus Amebocyte Lysate (LAL) testing to confirm that bacterial endotoxin levels remain below 0.01 EU/mg, making it suitable for sensitive cell culture and in vitro biochemical applications.
How does PT-141 differ chemically from Melanotan II?
PT-141 (Bremelanotide) is a carboxylic acid metabolite derivative of Melanotan II. It features a modified sequence designed to reduce binding affinity at cutaneous MC1R while retaining potent central MC4R/MC3R agonist activity.
Can institutions request lot-specific COAs before placing an order?
Yes. PX1 Research maintains lot-traceable raw data and COAs for every production batch. Researchers can review HPLC chromatograms, MS spectra, and endotoxin reports prior to or alongside shipment.
Is PT-141 approved for human clinical use or administration?
No. PT-141 provided by PX1 Research is strictly designated for laboratory research use only (RUO), including in vitro cellular assays and preclinical animal models. It is not for human, clinical, or therapeutic application.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.